INTELLIA THERAPEUTICS, INC.

(NTLA)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
59.56 USD   -7.18%
08/05SECTOR UPDATE : Health Care Stocks Drifting Lower Near Friday Close
MT
08/05SECTOR UPDATE : Health Care
MT
08/05Goldman Sachs Adjusts Price Target for Intellia Therapeutics to $159 From $180, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care Stocks Edge Higher Premarket Friday

06/24/2022 | 09:13am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
EMERGENT BIOSOLUTIONS INC. -3.27% 28.43 Delayed Quote.-34.60%
GSK PLC 1.46% 1418.96 Delayed Quote.-29.52%
INTELLIA THERAPEUTICS, INC. -7.18% 59.56 Delayed Quote.-49.63%
NASDAQ COMPOSITE -1.25% 12938.12 Real-time Quote.-16.25%
REGENERON PHARMACEUTICALS, INC. -1.91% 636.34 Delayed Quote.0.76%
SANOFI 0.77% 82.3 Real-time Quote.-7.80%
All news about INTELLIA THERAPEUTICS, INC.
08/05SECTOR UPDATE : Health Care Stocks Drifting Lower Near Friday Close
MT
08/05SECTOR UPDATE : Health Care
MT
08/05Goldman Sachs Adjusts Price Target for Intellia Therapeutics to $159 From $180, Maintai..
MT
08/05Credit Suisse Raises Intellia Therapeutics' Price Target to $101 from $98, Keeps Outper..
MT
08/05Piper Sandler Adjusts Price Target on Intellia Therapeutics to $163 From $171, Reiterat..
MT
08/05Wedbush Cuts Price Target on Intellia Therapeutics to $58 From $68, After Q2 Report, Al..
MT
08/05Chardan Research Cuts Price Target on Intellia Therapeutics to $146 From $172, Citing Q..
MT
08/04INTELLIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
08/04Intellia Therapeutics Reports Wider Q2 Net Loss; Shares Slip
MT
08/04TRANSCRIPT : Intellia Therapeutics, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
More news
Analyst Recommendations on INTELLIA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 49,6 M - -
Net income 2022 -444 M - -
Net cash 2022 625 M - -
P/E ratio 2022 -10,2x
Yield 2022 -
Capitalization 4 527 M 4 527 M -
EV / Sales 2022 78,7x
EV / Sales 2023 84,3x
Nbr of Employees 485
Free-Float 90,3%
Chart INTELLIA THERAPEUTICS, INC.
Duration : Period :
Intellia Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTELLIA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 59,56 $
Average target price 123,21 $
Spread / Average Target 107%
EPS Revisions
Managers and Directors
John M. Leonard President, Chief Executive Officer & Director
Glenn Goddard Treasurer, Chief Financial & Accounting Officer
Frank A. G. M. Verwiel Chairman
Laura Sepp-Lorenzino Chief Scientific Officer & Executive VP
Eliana Clark Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INTELLIA THERAPEUTICS, INC.-49.63%4 527
MODERNA, INC.-37.79%65 706
IQVIA HOLDINGS INC.-13.27%45 640
LONZA GROUP AG-26.68%43 587
SEAGEN INC.10.47%31 450
ALNYLAM PHARMACEUTICALS, INC.31.58%27 384